|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Found 465 studies with search of: | Open Studies | "Multiple Myeloma" |
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
|
||||
| 2 | Not yet recruiting |
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
|
||||
| 3 | Not yet recruiting |
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
|
||||
| 4 | Recruiting |
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
|
||||
| 5 | Recruiting |
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
|
||||
| 6 | Recruiting |
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
|
||||
| 7 | Recruiting |
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Persistent Multiple Myeloma
|
||||
| 8 | Recruiting |
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
||||
| 9 | Recruiting |
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
|
||||
| 10 | Recruiting |
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
|
||||
| 11 | Recruiting |
Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
|
||||
| 12 | Recruiting |
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
|
||||
| 13 | Recruiting |
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
|
||||
| 14 | Recruiting |
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
||||
| 15 | Recruiting |
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
|
||||
| 16 | Recruiting |
Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma
|
||||
| 17 | Recruiting |
Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
|
||||
| 18 | Recruiting |
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
|
||||
| 19 | Recruiting |
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
|
||||
| 20 | Recruiting |
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
|
|
Previous Page | Studies Shown (1-20) | Next Page (21-40) |
|